| [1] |
李苏宁，陈祚，王增武，等.我国老年高血压现状分析[J].中华高血压杂志，2019，27(2): 140-150.
|
| [2] |
United Nations Department of Economic and Social Affairs. Our world is growing older: UN DESA releases new report on ageing[EB/OL]. [2021-07-02](2019-10-10).
URL
|
| [3] |
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2015, 385(9963):117-171.
|
| [4] |
Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859):2224-2260.
|
| [5] |
Kario K. The Sacubitril/Valsartan, a first-in-class, angiotensin receptor neprilysin inhibitor (ARNI): Potential uses in hypertension, heart failure, and beyond[J]. Curr Cardiol Rep, 2018, 27, 20(1):5.
|
| [6] |
|
| [7] |
Williams B, Cockcroft JR, Kario K, et al. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: The PARAMETER study[J]. Hypertension, 2017, 69(3):411-420.
|
| [8] |
张存泰，陶军，田小利，等.血管衰老临床评估与干预中国专家共识（2018）[J].中华老年病研究电子杂志，2019，6(1): 1-8.
|
| [9] |
Nilsson PM. Hemodynamic aging as the consequence of structural changes associated with early vascular aging (EVA)[J]. Aging Dis, 2014, 5(2):109-113.
|
| [10] |
张彩情，洪华山.衰老心血管事件链[J].中华老年医学杂志，2019，38(10): 1180-1184.
|
| [11] |
Lambert EA, Chatzivlastou K, Schlaich M, et al. Morning surge in blood pressure is associated with reactivity of the sympathetic nervous system[J]. Am J Hypertens, 2014, 27(6):783-792.
|
| [12] |
胡大一，刘梅林，郭艺芳.老年高血压的诊断与治疗中国专家共识(2017版)[J].中华内科杂志，2017，56(11): 885-893.
|
| [13] |
张洁，郭立新.糖尿病自主神经病变与餐后低血压的机制研究[J].中华内分泌代谢杂志，2017，33(8): 699-701.
|
| [14] |
Blaustein MP, Leenen FH, Chen L, et al. How NaCl raises blood pressure: A new paradigm for the pathogenesis of salt-dependent hypertension[J]. Am J Physiol Heart Circ Physiol, 2012, 302(5):H1031-H1049.
|
| [15] |
Oh YS, Appel LJ, Galis ZS, et al. National heart, lung, and blood institute working group report on salt in human health and sickness: Building on the current scientific evidence[J]. Hypertension, 2016, 68(2):281-288.
|
| [16] |
Cuspidi C, Sala C, Tadic M, et al. Clinical and prognostic significance of a reverse dipping pattern on ambulatory monitoring: An updated review[J]. J Clin Hypertens (Greenwich), 2017, 19(7):713-721.
|
| [17] |
Elesgaray R, Caniffi C, Ierace DR, et al. Signaling cascade that mediates endothelial nitric oxide synthase activation induced by atrial natriuretic peptide.[J]. Regul Pept, 2008, 151(1-3):130-134.
|
| [18] |
Kurtz A, Della Bruna R, Pfeilschifter J, et al. Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process[J]. Proc Natl Acad Sci USA, 1986, 83(13):4769-4773.
|
| [19] |
Brenner BM, Ballermann BJ, Gunning ME, et al. Diverse biological actions of atrial natriuretic peptide[J]. Physiol Rev, 1990, 70(3):665-699.
|
| [20] |
Volpe M, Cuocolo A, Vecchione F, et al. Vagal mediation of the effects of atrial natriuretic factor on blood pressure and arterial baroreflexes in the rabbit[J]. Circ Res, 1987, 60(5):747-755.
|
| [21] |
Shi J, Wang X, Nguyen J, et al. Sacubitril is selectively activated by carboxylesterase 1 (CES1) in the liver and the activation is affected by CES1 genetic variation[J]. Drug Metab Dispos, 2016, 44(4):554-559.
|
| [22] |
Andersen MB, Simonsen U, Wehland M, et al. LCZ696(valsartan/sacubitril) a possible new treatment for hypertension and heart failure[J]. Basic Clin Pharmacol Toxicol, 2016, 118(1):14-22.
|
| [23] |
Ruilope LM, Dukat A, Bohm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study[J]. Lancet, 2010, 375(9722):1255-1266.
|
| [24] |
Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: A randomized, double-blind, placebo-controlled study[J]. Hypertension, 2014, 63(4):698-705.
|
| [25] |
Ito S, Satoh M, Tamaki Y, et al. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction[J]. Hypertens Res, 2015, 38(4):269-275.
|
| [26] |
Bavishi C, Messerli FH, Kadosh B, et al. Role of neprilysin inhibitor combinations in hypertension: Insights from hypertension and heart failure trials[J]. Eur Heart J, 2015, 36(30):1967-1973.
|
| [27] |
Kario K, Tamaki Y, Okino N, et al. LCZ696, a First-in-class angiotensin receptor-neprilysin inhibitor: The first clinical experience in patients with severe hypertension[J]. J Clin Hypertens (Greenwich), 2016,18(4):308-314.
|
| [28] |
Supasyndh O, Sun N, Kario K, et al. Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension[J]. Hypertens Res, 2017, 40(5):472-476.
|
| [29] |
Wang TD, Tan RS, Lee HY, et al. Effects of sacubitril/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension[J]. Hypertension, 2017, 69(1):32-41.
|
| [30] |
Wang JG, Yukisada K, Sibulo A Jr, et al. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy[J]. J Hypertens, 2017, 35(4):877-885.
|
| [31] |
Li Q, Li L, Wang F, et al. Effect and safety of LCZ696 in the treatment of hypertension: A meta-analysis of 9 RCT studies[J]. Medicine (Baltimore), 2019, 98(28):e16093.
|
| [32] |
McMurray JJ, Packer M, Desai AS, et al. PARADIGM-HF investigators and committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11):993-1004.
|
| [33] |
Supasyndh O, Wang J, Hafeez K, et al. Efficacy and safety of sacubitril/valsartan (LCZ696) compared with olmesartan in elderly asian patients (≥65 years) with systolic hypertension[J]. Am J Hypertens, 2017, 30(12):1163-1169.
|
| [34] |
Kario K. Proposal of a new strategy for ambulatory blood pressure profile-based management of resistant hypertension in the era of renal denervation[J]. Hypertens Res, 2013, 36(6):478-484.
|
| [35] |
Uzu T, Kimura G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension[J]. Circulation, 1999, 100(15):1635-1638.
|
| [36] |
Kimura G, Dohi Y, Fukuda M. Salt sensitivity and circadian rhythm of blood pressure: The keys to connect CKD with cardiovascular events[J]. Hypertens Res, 2010, 33(6):515-520.
|
| [37] |
Boggia J, Li Y, Thijs L, et al. International database on ambulatory blood pressure monitoring in relation to cardiovascular outcomes (IDACO) investigators. Prognostic accuracy of day versus night ambulatory blood pressure: A cohort study[J]. Lancet, 2007, 370(9594):1219-1229.
|
| [38] |
Haynes R, Judge P, Staplin N, et al. Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom heart and renal protection (HARP)-Ⅲ-rationale, trial design and baseline data[J]. Nephrol Dial Transplant, 2017, 32(12):2043-2051.
|
| [39] |
Jordan J, Stinkens R, Jax T, et al. Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension[J]. Clin Pharmacol Ther, 2017, 101(2):254-263.
|
| [40] |
Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines[J]. J Hypertens, 2020, 38(6):982-1004.
|
| [41] |
中国医疗保健国际交流促进会高血压分会，中国医师协会心血管分会，中国高血压联盟，等.沙库巴曲缬沙坦钠在高血压患者临床应用的中国专家建议[J].中华高血压杂志，2021，29(2): 108-114.
|